SHATTUCK LABS INC. - COMMON STOCK

Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors

04 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

29 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Participation in Upcoming March Conferences

26 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases

13 Feb 2024 05:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024

08 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference

04 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

21 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

13 Dec 2023 05:00:00 By Nasdaq GlobeNewswire

Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation Data from the American Society of Hematology (ASH) 2023 Annual Meeting on December 13, 2023

05 Dec 2023 15:15:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference

14 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights

09 Nov 2023 05:00:00 By Nasdaq GlobeNewswire

Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023

06 Nov 2023 08:28:40 By Nasdaq GlobeNewswire

Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annual Meeting

02 Nov 2023 08:01:00 By Nasdaq GlobeNewswire

Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights

10 Aug 2023 15:00:00 By Nasdaq GlobeNewswire

Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

25 May 2023 16:15:39 By Nasdaq GlobeNewswire

Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights

09 May 2023 15:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Participation in Upcoming 22nd Annual Needham Virtual Healthcare Conference

03 Apr 2023 06:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting

16 Mar 2023 07:31:26 By Nasdaq GlobeNewswire

Shattuck Labs Announces Participation in Upcoming March Conferences

01 Mar 2023 06:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates

23 Feb 2023 15:30:00 By Nasdaq GlobeNewswire